Concentra Group Holdings Parent, Inc. filings document the public reporting of a NYSE-listed occupational health services company with common stock registered under the symbol CON. Recent Form 8-K disclosures cover results of operations and financial condition, Regulation FD presentations, dividend declarations, preliminary operating metrics, and material executive and compensation matters.
The company's proxy and annual-meeting filings disclose board elections, advisory executive compensation votes, auditor ratification, stockholder voting results, and governance procedures. Other filings describe executive equity awards under the 2024 Equity Incentive Plan, leadership succession disclosures, and the company's Delaware corporate and capital-stock structure.
Concentra Group Holdings Parent, Inc. director Brigid A. Bonner received a grant of 3,989 shares of restricted stock on November 3, 2026, bringing her direct common stock holdings to 19,485 shares.
Concentra Group Holdings Parent, Inc. director Cheryl Pegus received a grant of 3,989 shares of restricted stock on November 3, 2026. Following the grant, she directly held 24,729 shares. The restricted stock, subject to certain exceptions, will vest in full on November 3, 2027, the first anniversary of the grant date.
Concentra Group Holdings Parent, Inc. reported that Executive Vice President and Chief People Officer Danielle Kendall received a direct grant of 33,245 shares of restricted stock on November 3, 2026. Her reported direct holdings after the grant were 109,310 shares.
Concentra Group Holdings Parent, Inc. (CON) executive vice president, chief operating officer - West Douglas R. McAndrew received a grant of 53,191 shares of restricted stock on November 3, 2026. The shares are scheduled to vest in equal annual installments over four years. His reported direct common-stock holdings following the grant were 167,288 shares.
Concentra Group Holdings Parent, Inc. director Daniel Thomas received a grant of 3,989 shares of restricted stock on November 3, 2026. His directly held position after the grant was 77,989 shares. Subject to certain exceptions, the award will vest in full on November 3, 2027.
Concentra Group Holdings Parent, Inc. (CON) Executive Vice President and Chief Clinical Services Officer Giovanni Gallara acquired 53,191 shares of restricted stock on November 3, 2026, at $0.00 per share. The grant will vest in equal annual installments over four years. Gallara directly held 166,628 shares after the transaction.
Concentra Group Holdings Parent, Inc. reported that Executive Vice President, Chief Reimbursement & Government Relations Officer Greg M. Gilbert received a 46,543-share restricted-stock award on November 3, 2026. The grant was recorded as a direct acquisition, bringing his reported direct common-stock holdings to 160,640 shares. The transaction is an award acquisition rather than a market purchase or sale.
Concentra Group Holdings Parent, Inc. (CON) reports that Executive Vice President, Chief Growth & Customer Officer Jonathan P. Conser received an award of 53,191 shares of restricted stock on November 3, 2026. Conser held 167,288 shares directly following the award.
Concentra Group Holdings Parent, Inc. (CON) Executive Vice President, Chief Information & Technology Officer John A. deLorimier received a grant of 46,543 shares of restricted stock on November 3, 2026. The shares will vest in equal annual installments over four years. His reported direct holdings after the grant were 160,115 shares of Common Stock.
Concentra Group Holdings Parent, Inc. director and President & Chief Executive Officer Matthew T. DiCanio acquired 164,894 shares of restricted stock as a grant on November 3, 2026. His reported directly held position following the grant was 507,186 shares. No Rule 10b5-1 plan is reported.